Quality of Life in the Trastuzumab for Gastric Cancer Trial
Open Access
- 20 June 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (7) , 712-719
Abstract
Background.: The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial.Patients and Methods.: Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients.Results.: Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone.Conclusion.: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.Keywords
Funding Information
- F. Hoffmann-La Roche Ltd
This publication has 23 references indexed in Scilit:
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard?Current Treatment Options in Oncology, 2011
- HER2 Testing in Gastric CancerAdvances in Anatomic Pathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeNew England Journal of Medicine, 2007
- Analyzing Oncology Clinical Trial Data Using the Q-TWiST Method: Clinical Importance and Sources for Health State Preference Data*Quality of Life Research, 2006
- Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancerEuropean Journal of Cancer, 2004
- Development of an EORTC disease-specific quality of life module for use in patients with gastric cancerEuropean Journal of Cancer, 2001
- Oncologists' use of quality of life information: Results of a survey of Eastern Cooperative Oncology Group physiciansQuality of Life Research, 2001
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993